USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
27 Jan 2022 | 03:45 PM GMT

Companion DTx in Oncology: Opportunities for pharma

Anchored by:

Alexander Klein
Founder & CEO
NEDICARE
Myles Furnace
Chief Commercial Officer
EOLAS MEDICAL

Participants:

Alexander Klein Founder & CEONedicare
Alexander Klein
Founder & CEONedicare
Myles Furnace Chief Commercial OfficerEolas Medical
Myles Furnace
Chief Commercial OfficerEolas Medical
Anish Shindore Founder & Managing PartnerGSD Health
Anish Shindore
Founder & Managing PartnerGSD Health
Brian Flatley VP Consulting Services & US Pharma SolutionsS3 Connected Health
Brian Flatley
VP Consulting Services & US Pharma SolutionsS3 Connected Health
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Gandolf Finke CEOSynagen
Gandolf Finke
CEOSynagen
Jin Lee Director of Digital HealthAstellas Pharma, Inc
Jin Lee
Director of Digital HealthAstellas Pharma, Inc
Jyri Yli-Villamo Head of Pharma Global Strategic PartnershipsKaiku Health
Jyri Yli-Villamo
Head of Pharma Global Strategic PartnershipsKaiku Health
Maike Schmitz Oncology LeadRoX Health GmbH
Maike Schmitz
Oncology LeadRoX Health GmbH
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Smit Patel AdvisorEconomist Impact
Smit Patel
AdvisorEconomist Impact
Tahir Hussain Global Pharma Business Dev. Digital HealthBiofourmis
Tahir Hussain
Global Pharma Business Dev. Digital HealthBiofourmis

About this Meeting

DTx solutions as digital drug companions are starting to show promise as valuable routes for market differentiation. There is more and more interest in drug-device combination products, propelled by COVID-19 and increased investment in DTx solutions in general. 

 Oncology treatments usually lead to adverse effects that compromise patients quality of life, hence it seems that the opportunity for DTx is particularly great in this therapeutic area. Join the meeting to discuss the following: 

  •  How can pharma leverage DTx to improve patients’ experience with their drugs? What is the ROI for pharma?  
  •  When is the right moment to incorporate the DTx (during trials, promotion, or other)? Can drug-DTx combo in oncology ease the market access process of the drug?
  • Beyond financial reasons, what are the main drivers for pharma to incorporate digital health solutions in the care plans of their oncological drugs?
  •  How to choose the right companion for a specific drug?  
  •  We have seen promising partnerships being formed in the last few years, such as, for instance, the collaboration between Voluntis and AstraZeneca as well as BMS, and Kaiku Health teaming up with Novartis and Roche. What are the results and key learnings of these partnerships so far?